Download PDF
Thromb Haemost 2014; 111(01): 88-93
DOI: 10.1160/TH13-01-0042
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients

Tzu-Fei Wang
1   Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio, USA
2   Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA
,
Paul E. Milligan
2   Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA
3   Center for Clinical Excellence, BJC HealthCare, Saint Louis, Missouri, USA
,
Catherine A. Wong
3   Center for Clinical Excellence, BJC HealthCare, Saint Louis, Missouri, USA
,
Eli N. Deal
4   Department of Pharmacy, Barnes-Jewish Hospital, Saint Louis, Missouri, USA
,
Mark S. Thoelke
2   Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA
,
Brian F. Gage
2   Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA
› Author Affiliations Financial support: This study was funded in part by the BJC Center for Clinical Excellence and the NIH (R01 HL 097036).
Further Information

Publication History

Received: 16 January 2013

Accepted after major revision: 12 September 2013

Publication Date:
29 November 2017 (online)

    Permissions and Reprints

Summary

Obesity increases the risk for venous thromboembolism (VTE), but whether high-dose thromboprophylaxis is safe and effective in morbidly obese inpatients is unknown. It was the objective of this study to quantify the efficacy and safety of high-dose thromboprophylaxis with heparin or enoxaparin in inpatients with weight > 100 kilograms (kg) within the BJC HealthCare system. In a retrospective cohort study, we analysed 9,241 inpatients with weight < 100 kg discharged from three hospitals in the BJC HealthCare system from 2010 through 2012. We compared the incidence of VTE in patients who received high-dose thromboprophylaxis (heparin 7,500 units three times daily or enoxaparin 40 mg twice daily) to those who received standard doses (heparin 5,000 units two or three times daily or enoxaparin 40 mg once daily). The primary efficacy outcome was hospital-acquired VTE identified by International Classification of Diseases (ICD)-9 diagnosis codes. The primary safety outcome was bleeding events identified by ICD-9 codes. Among the 3,928 morbidly obese inpatients (weight > 100 kg and body mass index [BMI] ≥ 40 kg/m2), high-dose thromboprophylaxis approximately halved the odds of symptomatic VTE (odds ratio [OR] 0.52, 95% confidence interval [CI] 0.27–1.00; p = 0.050). The rate of VTE was 1.48% (35/2,369) in these morbidly obese inpatients who received standard doses of thromboprophylaxis, compared to 0.77% (12/1,559) in those who received high doses. High-dose thromboprophylaxis did not increase bleeding (OR 0.84, 95% CI 0.66–1.07, p = 0.15). Independent predictors of VTE were surgery, male sex, cancer, and BMI. In conclusion, high-dose thromboprophylaxis nearly halves the rate of VTE in morbidly obese inpatients.

Keywords

Obesity - obese inpatient - thromboprophylaxis - venous thromboembolism
 

  • References

  • 1 Wattanakit K, Lutsey PL, Bell EJ. et al. Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis. Thromb Haemost 2012; 108: 508-515.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Morange PE, Alessi MC. Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology. Thromb Haemost 2013; 110: 669-680.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Goldhaber SZ, Grodstein F, Stampfer MJ. et al. A prospective study of risk factors for pulmonary embolism in women. J Am Med Assoc 1997; 277: 642-645.
    CrossrefPubMedGoogle Scholar
  • 4 Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005; 118: 978-980.
    CrossrefPubMedGoogle Scholar
  • 5 Pomp ER, le Cessie S, Rosendaal FR. et al. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139: 289-296.
    CrossrefPubMedGoogle Scholar
  • 6 Allman-Farinelli MA. Obesity and venous thrombosis: a review. Semin Thromb Hemost 2011; 37: 903-907.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Rocha AT, de Vasconcellos AG, da Luz Neto ER. et al. Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obes Surg 2006; 16: 1645-1655.
    CrossrefPubMedGoogle Scholar
  • 8 Shibuya N, Frost CH, Campbell JD. et al. Incidence of acute deep vein thrombosis and pulmonary embolism in foot and ankle trauma: analysis of the National Trauma Data Bank. J Foot Ankle Surg 2012; 51: 63-68.
    CrossrefPubMedGoogle Scholar
  • 9 Smith SB, Geske JB, Morgenthaler TI. Risk factors associated with delayed diagnosis of acute pulmonary embolism. J Emerg Med 2012; 42: 1-6.
    CrossrefPubMedGoogle Scholar
  • 10 Tick LW, Kramer MH, Rosendaal FR. et al. Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis. J Thromb Haemost 2008; 6: 2075-2081.
    CrossrefPubMedGoogle Scholar
  • 11 Blaszyk H, Bjornsson J. Factor V leiden and morbid obesity in fatal postoperative pulmonary embolism. Arch Surg 2000; 135: 1410-1413.
    CrossrefPubMedGoogle Scholar
  • 12 Blaszyk H, Wollan PC, Witkiewicz AK. et al. Death from pulmonary throm-boembolism in severe obesity: lack of association with established genetic and clinical risk factors. Virchows Arch 1999; 434: 529-532.
    CrossrefPubMedGoogle Scholar
  • 13 White RH, Gettner S, Newman JM. et al. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000; 343: 1758-1764.
    CrossrefPubMedGoogle Scholar
  • 14 Raschke RA, Reilly BM, Guidry JR. et al. The weight-based heparin dosing no-mogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med 1993; 119: 874-881.
    CrossrefPubMedGoogle Scholar
  • 15 Umscheid CA, Agarwal R, Gibson G. Weight-based low-molecular-weight he-parin versus weight-based intravenous unfractionated heparin. Ann Intern Med 2007; 147: 433-434 author reply 434
    CrossrefPubMedGoogle Scholar
  • 16 Samama MM, Cohen AT, Darmon JY. et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800.
    CrossrefPubMedGoogle Scholar
  • 17 Nutescu EA, Spinler SA, Wittkowsky A. et al. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009; 43: 1064-1083.
    CrossrefPubMedGoogle Scholar
  • 18 Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 2003; 90: 547-548.
    CrossrefPubMedGoogle Scholar
  • 19 Rowan BO, Kuhl DA, Lee MD. et al. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg 2008; 18: 162-166.
    CrossrefPubMedGoogle Scholar
  • 20 Rondina MT, Wheeler M, Rodgers GM. et al. Weight-based dosing of enoxapa-rin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res 2010; 125: 220-223.
    CrossrefPubMedGoogle Scholar
  • 21 Freeman AL, Pendleton RC, Rondina MT. Prevention of venous thromboem-bolism in obesity. Expert Rev Cardiovasc Ther 2010; 8: 1711-1721.
    CrossrefPubMedGoogle Scholar
  • 22 Freeman A, Horner T, Pendleton RC. et al. Prospective comparison of three en-oxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol 2012; 87: 740-743.
    CrossrefPubMedGoogle Scholar
  • 23 Deal EN, Hollands JM, Reichley RM. et al. Characteristics of patients with morbid obesity at an academic medical center. Am J Health Syst Pharm 2010; 67: 1589-1590.
    CrossrefPubMedGoogle Scholar
  • 24 Bakirhan K, Strakhan M. Pharmacologic prevention of venous thromboembol-ism in obese patients. J Thromb Thrombolysis 2013; 36: 247-257.
    CrossrefPubMedGoogle Scholar
  • 25 White RH, Beyth RJ, Zhou H. et al. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999; 107: 414-424.
    CrossrefPubMedGoogle Scholar
  • 26 Birman-Deych E, Waterman AD, Yan Y. et al. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 2005; 43: 480-485.
    CrossrefPubMedGoogle Scholar
  • 27 Quan H, Sundararajan V, Halfon P. et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139.
    CrossrefPubMedGoogle Scholar
  • 28 Turner K, Burchill C. This is the Charlson Comorbidity Index macro code using ICD-9-CM. Available at: http://mchpappserv.cpe.umanitoba.ca/concept_CharlsonICD9CM.sas.txt . Accessed April 7, 2013.
    PubMedGoogle Scholar
  • 29 Badimon L, Hernandez Vera R, Padro T. et al. Antithrombotic therapy in obesity. Thromb Haemost 2013; 110: 681-688.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Rosito GA, DAgostino RB, Massaro J. et al. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 2004; 91: 683-689.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Eichinger S, Hron G, Bialonczyk C. et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008; 168: 1678-1683.
    CrossrefPubMedGoogle Scholar
  • 32 Darvall KA, Sam RC, Silverman SH. et al. Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007; 33: 223-233.
    CrossrefPubMedGoogle Scholar
  • 33 Ay L, Kopp HP, Brix JM. et al. Thrombin generation in morbid obesity: significant reduction after weight loss. J Thromb Haemost 2010; 8: 759-765.
    CrossrefPubMedGoogle Scholar
  • 34 Semeraro F, Giordano P, Faienza MF. et al. Evidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic state: relative contribution of TAFI and PAI-1. Thromb Haemost 2012; 108: 311-317.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Christiansen SC, Lijfering WM, Naess IA. et al. The relationship between body mass index, activated protein C resistance and risk of venous thrombosis. J Thromb Haemost 2012; 10: 1761-1767.
    CrossrefPubMedGoogle Scholar
  • 36 White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: I4-8.
    CrossrefPubMedGoogle Scholar
  • 37 Silverstein MD, Heit JA, Mohr DN. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
    CrossrefPubMedGoogle Scholar
  • 38 Finks JF, English WJ, Carlin AM. et al. Predicting risk for venous thromboem-bolism with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative. Ann Surg 2012; 255: 1100-1104.
    CrossrefPubMedGoogle Scholar
  • 39 Imberti D, Bianchi C, Zambon A. et al. Venous thromboembolism after major orthopaedic surgery: a population-based cohort study. Intern Emerg Med 2012; 7: 243-249.
    CrossrefPubMedGoogle Scholar
  • 40 Douketis J, Tosetto A, Marcucci M. et al. Risk of recurrence after venous throm-boembolism in men and women: patient level meta-analysis. Br Med J 2011; 342: d813
    CrossrefPubMedGoogle Scholar
  • 41 Blom JW, Doggen CJ, Osanto S. et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Am Med Assoc 2005; 293: 715-722.
    CrossrefPubMedGoogle Scholar
  • 42 Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012; 9: e1001275
    CrossrefPubMedGoogle Scholar
  • 43 Anderson Jr. FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107 (23) (Suppl. 01) I9-16.
    CrossrefPubMedGoogle Scholar
  • 44 Borkgren-Okonek MJ, Hart RW, Pantano JE. et al. Enoxaparin thromboprophy-laxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 2008; 4: 625-631.
    CrossrefPubMedGoogle Scholar
  • 45 Singh K, Podolsky ER, Um S. et al. Evaluating the safety and efficacy of BMI-based preoperative administration of low-molecular-weight heparin in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg 2012; 22: 47-51.
    CrossrefPubMedGoogle Scholar
  • 46 Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002; 12: 19-24.
    CrossrefPubMedGoogle Scholar
  • 47 Ludwig KP, Simons HJ, Mone M. et al. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. Ann Pharmacother 2011; 45: 1356-1362.
    CrossrefPubMedGoogle Scholar
  • 48 Kucher N, Koo S, Quiroz R. et al. Electronic alerts to prevent venous throm-boembolism among hospitalized patients. N Engl J Med 2005; 352: 969-977.
    CrossrefPubMedGoogle Scholar
  • 49 Hijazi MH DT. Multidisciplinary approach improves compliance with venous thromboembolism prophylaxis. Chest 2009; 136: 150S
    CrossrefPubMedGoogle Scholar